EP1339438A2 — Methods for preventing transplant rejection in the eye
Assigned to Allergan Inc · Expires 2003-09-03 · 23y expired
What this patent protects
Methods for reducing or preventing transplant rejection in the eye of an individual are described; comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible pol…
USPTO Abstract
Methods for reducing or preventing transplant rejection in the eye of an individual are described; comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.